Letters6 July 2010Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI TrialS. Mitchell Harman, MD, PhD, Eliot A. Brinton, MD, Frederick Naftolin, MD, PhD, George R. Merriam, MD, Marcelle I. Cedars, MD, Ruth G. Freeman, MD, and Nanette Santoro, MDS. Mitchell Harman, MD, PhDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, Eliot A. Brinton, MDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, Frederick Naftolin, MD, PhDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, George R. Merriam, MDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, Marcelle I. Cedars, MDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, Ruth G. Freeman, MDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this author, and Nanette Santoro, MDFrom Kronos Longevity Research Institute, Phoenix, AZ 85016; University of Utah School of Medicine, Salt Lake City, UT 84108; New York University School of Medicine, New York, NY 10016; University of Washington School of Medicine, Seattle, WA 98195; University of California at San Francisco, San Francisco, CA 94115; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461; and University of Colorado at Denver, Aurora, CO 80045.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-1-201007060-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We applaud Toh and colleagues (1) for delving deeper into the still-controversial issue of inconsistencies in the outcomes of cardiovascular disease (CVD) between the Women's Health Initiative (WHI) estrogen plus progestin hormone trial and previous large observational studies. Current evidence suggests that both the timing of initiation and the duration of menopausal hormone therapy (2, 3) are important determinants of the risk–benefit ratio. The data presented by Toh and colleagues suggest that the slightly higher CVD risk in the first 2 years of treatment leads to a lower risk after 6 or more years of use only ...
Read more